[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR910700069A - Gm-csf를 사용한 백혈구 기능장애의 치료 - Google Patents

Gm-csf를 사용한 백혈구 기능장애의 치료

Info

Publication number
KR910700069A
KR910700069A KR1019900702160A KR900702160A KR910700069A KR 910700069 A KR910700069 A KR 910700069A KR 1019900702160 A KR1019900702160 A KR 1019900702160A KR 900702160 A KR900702160 A KR 900702160A KR 910700069 A KR910700069 A KR 910700069A
Authority
KR
South Korea
Prior art keywords
csf
leukocyte
physical trauma
leukocyte dysfunction
mammal
Prior art date
Application number
KR1019900702160A
Other languages
English (en)
Other versions
KR0137361B1 (ko
Inventor
엠. 본엠 에릭
Original Assignee
스타이너 브이. 캔스타드
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타이너 브이. 캔스타드, 쉐링 코포레이션 filed Critical 스타이너 브이. 캔스타드
Publication of KR910700069A publication Critical patent/KR910700069A/ko
Application granted granted Critical
Publication of KR0137361B1 publication Critical patent/KR0137361B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • External Artificial Organs (AREA)

Abstract

내용 없음.

Description

GM-CSF를 사용한 백혈구 기능장애의 치료
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 GM-CSF로 치료한 화상 환자내에서 단핵구의 증가된 증식을 나타낸 그래프이다.
제2 내지 3도는 GM-CSF로 치료한 화상 환자의 증진된 단핵구의 파열을 나타낸 그래프이다.

Claims (10)

  1. 신체적 외상이 있는 포유동물에게 백혈구 기능을 가능케 하는 유효량의 GM-CSF를 투여함을 특징으로 하여 백혈구 기능장애를 치료하는 방법.
  2. 제1항에 있어서, GM-CSF가 용량당 약 2 내지 30㎍/체중(㎏)의 양으로 투여되는 방법.
  3. 제1항 내지 2항중 어느 한 항에 있어서, GM-CSF가 재조합 사람 GM-CSF인 방법.
  4. 제1항 내지 3항중 어느 한 항에 있어서, 투여가 정맥내 주입 또는 주사에 의해 이루어지는 방법.
  5. 제1항 내지 4항중 어느 한 항에 있어서, 투여가 약 4시간 주기에 걸쳐 이루어지는 방법.
  6. 제1항 내지 5항중 어느 한 항에 있어서, 용량이 약 3 내지 약 15㎍/체중(㎏)인 방법.
  7. 제1항 내지 6항중 어느 한 항에 있어서, 신체적 외상이 화상인 방법.
  8. 신체적 외상과 관련된 백혈구 기능장애가 있는 포유동물에게 백혈구 기능을 가능케 하는 유효량의 GM-CSF를 투시하여 포유동물을 치료하는 방법에 사용하기 위한 약제 제조용 GM-CSF의 용도.
  9. 신체적 외상과 관련된 백혈구 기능장애가 있는 환자를 치료하기 위한 GM-CSF의 용도.
  10. 신체적 외상과 관련된 백혈구 기능장애가 있는 환자를 치료하기 위해 사용되는 GM-CSF를 함유하는 약체학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900702160A 1989-01-30 1990-01-26 Gm-csf를 포함하는 백혈구 기능장애 치료조성물 KR0137361B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30439189A 1989-01-30 1989-01-30
US304,391 1989-01-30
US304.391 1989-01-30
PCT/US1990/000379 WO1990008554A1 (en) 1989-01-30 1990-01-26 Treatment of leukocyte dysfunction with gm-csf
USPUS90/00379 1990-01-26

Publications (2)

Publication Number Publication Date
KR910700069A true KR910700069A (ko) 1991-03-13
KR0137361B1 KR0137361B1 (ko) 1998-04-25

Family

ID=23176323

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702160A KR0137361B1 (ko) 1989-01-30 1990-01-26 Gm-csf를 포함하는 백혈구 기능장애 치료조성물

Country Status (21)

Country Link
US (1) US5178855A (ko)
EP (2) EP0382381B1 (ko)
JP (1) JPH0651640B2 (ko)
KR (1) KR0137361B1 (ko)
AT (1) ATE89737T1 (ko)
AU (1) AU633054B2 (ko)
CA (1) CA2045605C (ko)
DE (1) DE69001686T2 (ko)
DK (1) DK0382381T3 (ko)
ES (1) ES2055314T3 (ko)
FI (1) FI913625A0 (ko)
HK (1) HK46196A (ko)
HU (1) HU207229B (ko)
IE (1) IE64234B1 (ko)
IL (1) IL93219A (ko)
MY (1) MY105798A (ko)
NZ (1) NZ243953A (ko)
OA (1) OA09509A (ko)
PT (1) PT92995B (ko)
WO (1) WO1990008554A1 (ko)
ZA (1) ZA90600B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
EP0661057A4 (en) * 1993-06-08 1997-09-03 Ajinomoto Kk ACCELERATOR OF THE PROLIFERATION OF HEMATOPIETIC CELLS.
AU704486B2 (en) * 1994-03-04 1999-04-22 Ludwig Institute For Cancer Research Animals with targeted gene disruption
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP2010513525A (ja) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド 安定な抗嘔吐経口噴霧製剤および方法
US7826202B2 (en) * 2007-08-09 2010-11-02 Haworth, Inc. Modular electrical distribution system for a building

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
AU606585B2 (en) * 1985-10-03 1991-02-14 Biogen, Inc. Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
US4921837A (en) * 1985-11-27 1990-05-01 Genetics Institute Inc. Treatment of AIDS-type disease
ATE92966T1 (de) * 1986-05-06 1993-08-15 Genetics Inst Herstellung von m-csf.
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
WO1989004173A1 (en) * 1987-11-12 1989-05-18 Schering Corporation Acceleration of bone formation with gm-csf

Also Published As

Publication number Publication date
IE900318L (en) 1990-07-30
JPH0651640B2 (ja) 1994-07-06
HU207229B (en) 1993-03-29
HK46196A (en) 1996-03-22
NZ243953A (en) 1997-06-24
IL93219A (en) 1998-12-27
PT92995B (pt) 1995-12-29
AU5048890A (en) 1990-08-24
ATE89737T1 (de) 1993-06-15
IL93219A0 (en) 1990-11-05
ES2055314T3 (es) 1994-08-16
KR0137361B1 (ko) 1998-04-25
DE69001686T2 (de) 1993-09-02
EP0382381B1 (en) 1993-05-26
HUT57607A (en) 1991-12-30
MY105798A (en) 1995-01-30
IE64234B1 (en) 1995-07-26
JPH03504980A (ja) 1991-10-31
PT92995A (pt) 1990-07-31
EP0455726A1 (en) 1991-11-13
US5178855A (en) 1993-01-12
WO1990008554A1 (en) 1990-08-09
DK0382381T3 (da) 1993-07-12
ZA90600B (en) 1990-10-31
DE69001686D1 (de) 1993-07-01
EP0382381A1 (en) 1990-08-16
AU633054B2 (en) 1993-01-21
FI913625A0 (fi) 1991-07-30
CA2045605A1 (en) 1990-07-31
OA09509A (en) 1992-11-15
CA2045605C (en) 1997-02-11

Similar Documents

Publication Publication Date Title
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
JPS6425A (en) Medicinal composition for treating hiv infection containing dsrna and reverse transcriptase inhibitor
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
KR910700069A (ko) Gm-csf를 사용한 백혈구 기능장애의 치료
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
DE69739050D1 (de) Verwendung von Thrombopoietin als Medikament zur Therapie und Vorbeugung der Thrombocytopenie
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
KR910005858A (ko) 지방산 요법
Saphier et al. α-Interferon inhibits adrenocortical secretion via μ1-opioid receptors in the rat
PT651654E (pt) Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa
JP2005511563A (ja) チモシンα１ペプチドを投与する方法
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
KR890701526A (ko) 각화증 치료제
KR930003913A (ko) 덱스트로메토르판의 진해효과를 증진시키기 위한 방법 및 약제학적 조성물
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
Schanzer et al. Tissue damage caused by the intramuscular injection of long-acting penicillin
KR900701301A (ko) 후천성 면역 결핍증과 연관된 골수억제증의 치료방법
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
JPS6461420A (en) Alpha-ethiocholanedione drug, and method of causing high hematic concentration alpha-ethiocholanone
RU1803119C (ru) Способ лечени внематочной беременности
Miller et al. Effect of penicillin dosage schedule on treatment of experimental typhoid infections in mice
Akuginova Combination of antihelminthic drugs (phenasal and bithionole) for therapy of cestode inections. II. Investigation of the effectiveness of bithionole and of combination of bithionole with phenasal in treatment of taeniarhynchosis
SU799761A1 (ru) Способ лечени бруцеллеза
JPS6447715A (en) Improver for ovulation inductive pregnant genital physiological dysfunction
Rochon Beating HIV at its own game: the success of IL-2

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010118

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee